- Case-Based Roundtable
- General Dermatology
- Eczema
- Chronic Hand Eczema
- Chronic Spontaneous Urticaria
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
- Prurigo Nodularis
- Buy-and-Bill
Article
MacroChem announces phase 2 data for EcoNail in treatment of onychomychosis
New York - MacroChem Corporation announces results of a phase 2 clinical trial of EcoNail,a topical antifungal for the treatment of onychomychosis, according to Earthtimes.org.
New York
- MacroChem Corporation announces results of a phase 2 clinical trial of EcoNail,a topical antifungal for the treatment of onychomychosis, according to Earthtimes.org.
An expert panel assessed clinical photographs of 37 onychomychosis patients who completed 48 weeks of EnoNail treatment in the U.S. multi-center, open-label efficacy and safety study.
The panel observed that 24 patients (65 percent) showed evidence of clinical improvement.
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
